Popular Articles

Physio-Control Named A Medical Device Excellence Award Winner
Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc., (NYSE: MDT), announced that it has received a Gold Medical Design Excellence Award (MDEA) for its LIFEPAK® 15 monitor/defibrillator.

European CHMP Adopts Positive Opinion For Aztreonam Lysine
Gilead Sciences, Inc. (Nasdaq:GILD) announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company"s Marketing Authorisation Application for aztreonam lysine 75 mg powder and solvent for nebuliser solution (aztreonam lysine) for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 18 years and older. The opinion is for conditional approval, contingent on the successful completion of an ongoing study.
News of the day
OneTouch(R) Ping™ Glucose Management System Approved By Health Canada
Animas Corporation announcedthe approval of its OneTouch® Ping™ Glucose Management System by Health Canada. OneTouch Ping is the first full-feature insulin pump that wirelessly communicates with a blood glucose meter-remote. Using the OneTouch Ping meter-remote, a person can calculate insulin doses and opt to wirelessly instruct the pump to deliver them without touching the pump at all, giving patients more freedom and flexibility in using their insulin pump.
Medical Devices

Changing Paradigms In Hereditary Angioedema: Pathophysiology, Diagnosis And Treatment

Hereditary angioedema (HAE) is an autosomal dominant disease affecting between 4,000 and 10,000 people in the United States. HAE causes recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. While chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of HAE therapy, many new therapies for prophylaxis and acute treatment are on the horizon. It is important for physicians to understand the diagnostic strategies in HAE as well as the conventional and emerging therapeutic options available for HAE prophylaxis and acute attacks. To address the need for current education on HAE, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a complimentary continuing education monograph entitled Changing Paradigms in Hereditary Angioedema: Pathophysiology, Diagnosis and Treatment. The content for this monograph was derived from a live symposium which took place on February 13, 2009 in Fort Lauderdale, Florida. This activity is supported by an educational grant from ViroPharma Incorporated and is accredited for physicians. Faculty reviewers include Michael M. Frank, MD from Duke University School of Medicine in Durham, NC; Bruce L. Zuraw, MD from the University of California, San Diego School of Medicine in San Diego, CA; and Marc A. Riedl, MD from the University of California, Los Angeles David Geffen School of Medicine in Los Angeles, CA. "Quality continuing medical education is vital to developing and increasing knowledge and skills and enhancing patient care," says Robert Michael Educational Institute LLC President and CEO, Robert M. Colleluori. RMEI is a medical education company that specializes in independent, certified and non-certified education. The goal of all certified RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment leading to better outcomes for patients. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs. Robert Michael Educational Institute LLC


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):